NurExone Biologic Inc.
NRXBF
$0.50
$0.011.31%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -52.62% | -50.39% | -38.58% | -8.12% | -8.97% |
| Total Depreciation and Amortization | 189.80% | 169.05% | 157.58% | 58.06% | 226.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 94.66% | 80.31% | 50.23% | 102.35% | 143.84% |
| Change in Net Operating Assets | 192.81% | 98.96% | -23,175.00% | -227.00% | -209.22% |
| Cash from Operations | -22.60% | -23.05% | -66.20% | -22.25% | -19.69% |
| Capital Expenditure | -3.53% | -42.39% | -440.83% | -1,325.53% | -545.61% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -92.31% | -139.13% | -139.13% | -- | 135.14% |
| Cash from Investing | -7.04% | -56.99% | -578.35% | -1,297.87% | -277.66% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 44.12% | 10.71% | -7.14% | -55.00% | -183.33% |
| Issuance of Common Stock | -11.76% | -40.32% | 534.55% | 610.35% | 9,874.55% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -776.34% | -994.74% | -994.74% | -46.74% | -92.38% |
| Cash from Financing | -29.50% | -56.84% | 419.26% | 407.98% | 219.76% |
| Foreign Exchange rate Adjustments | -414.71% | -9,850.00% | -981.25% | 900.00% | 166.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -176.88% | -259.99% | 108.27% | 168.73% | 197.85% |